(Reuters) - Drugmaker AstraZeneca said on Friday its lung cancer drugs Imfinzi and Imjudo have been approved by the U.S. Food and Drug Administration (FDA) when used along with chemotherapy for treatment of adults with stage IV non-small cell lung cancer.
(Reuters) – Drugmaker AstraZeneca said on Friday its lung cancer drugs Imfinzi and Imjudo have been approved by the U.S. Food and Drug Administration (FDA) when used along with chemotherapy for treatment of adults with stage IV non-small cell lung cancer.
(Reporting by Amna Karimi in Bengaluru; Editing by Sherry Jacob-Phillips)
Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV. Learn more about Thomson Reuters products:
